
Neimeth had a strong turnaround year in 2025, moving from losses in 2024 to profitability.
What improved
• Revenue grew by 64%, meaning the company sold significantly more pharmaceutical products than last year.
• The company moved from a loss in 2024 to a profit in 2025.
• Earnings per share turned positive, rising from a loss of 21 kobo per share to a gain of 23 kobo per share.
What this means
• The results suggest stronger demand, better pricing, and improved cost control.
• The company has stabilised operations and is now making money again after a difficult year.
Share price insight
• The stock price is relatively high compared to its current earnings.
• This suggests investors are betting on continued improvement and future growth, not just current profits.
Neimeth’s 2025 results show a company back on its feet. Sales are up sharply, losses have been reversed, and shareholder earnings are positive again. The business appears to be on a recovery and growth path.

Leave A Reply